Alumis Inc. (NASDAQ:ALMS) Stock Holdings Increased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. grew its holdings in shares of Alumis Inc. (NASDAQ:ALMS) by 4.4% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 113,401 shares of the company’s stock after acquiring an additional 4,808 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.24% of Alumis worth $891,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Samsara BioCapital LLC acquired a new stake in Alumis in the third quarter worth about $34,886,000. Geode Capital Management LLC bought a new stake in shares of Alumis during the 3rd quarter worth about $3,266,000. Stifel Financial Corp acquired a new stake in shares of Alumis in the 3rd quarter worth approximately $931,000. State Street Corp bought a new position in shares of Alumis in the third quarter valued at approximately $866,000. Finally, Towerview LLC increased its stake in shares of Alumis by 9.2% during the fourth quarter. Towerview LLC now owns 415,000 shares of the company’s stock valued at $3,262,000 after acquiring an additional 35,000 shares during the period.

Alumis Stock Up 20.0 %

Shares of Alumis stock opened at $5.64 on Monday. Alumis Inc. has a 12-month low of $3.18 and a 12-month high of $13.53. The stock’s fifty day moving average is $5.39 and its 200-day moving average is $8.30.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Alumis in a research report on Wednesday, March 26th. Cantor Fitzgerald restated an “overweight” rating on shares of Alumis in a report on Thursday, March 20th. Finally, Oppenheimer began coverage on Alumis in a research note on Thursday, January 30th. They set an “outperform” rating and a $32.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $26.00.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.